Immunotherapy has become very promising treatment modality for patients with lung cancer. Despite these encouraging results, further progress must be made, both in terms of treatment modalities and how to select patients for immunotherapy.
The IASLC Lung Cancer Immunotherapy Meeting 2018 has both educational and scientific objectives. The main objective is to review the most recent scientific advances within immunotherapy for lung cancer and to make a roadmap for future studies to improve therapeutic results. The program includes invited lectures and panel discussions by world leaders in the field. Additionally, the methodology of how to best select patients for immunotherapy will be discussed. Furthermore. the program also emphasize future new perspectives such as immunoprevention of lung cancer.
The meeting is aimed for clinical and basic science investigators, as well as community-practicing physicians. Special workshops in the program are dedicated to nurses and patient advocates.
Hotel registration: meetings.melia.com/en/IASLCImmunotherapyMeeting.html